多西他赛联合奥沙利铂治疗晚期非小细胞肺癌的临床观察  

Effects of Combination Chemotherapy with Docetaxel and Oxaliplatin on Advanced Non-small-cell lung Cancer

作　　者：赵军[1] 杨瑞青[1] 郑法德[1] 刘斌[1] 周瑞清[1] 

机构地区：[1]阜阳市人民医院呼吸内科,安徽阜阳236004

出　　处：《临床肺科杂志》2012年第7期1283-1284,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的观察多西他赛联合奥沙利铂治疗晚期非小细胞肺癌的有效性和安全性。方法一线化疗失败的晚期非小细胞肺癌患者62例采用多西他赛联合奥沙利铂化疗,每3周重复,化疗3周期后,按WHO目标病灶缓解标准进行近期疗效和毒副反应评价。结果 62例患者均完成至少3周期化疗,总有效率35.4%,其中CR 3例,PR 19例。主要毒性为骨髓抑制,消化道反应,脱发等。结论多西他赛联合奥沙利铂治疗一线化疗失败的非小细胞肺癌有较好的确切疗效,并且毒性反应可以控制,耐受性好,可作为晚期非小细胞肺癌二线治疗的标准方案。Objective To investigate the therapeutic effect and adverse reactions of combination chemotherapy with Docetaxel and Oxaliplatin on non-small-cell lung cancer（NSCLC）.Methods 62 patients with advanced NSCLC failing in the first-line treatment received the combination chemotherapy with Docetaxel and Oxaliplatin.3 weeks was a cycle.The therapeutic effect and adverse reactions were evaluated on WHO target lesions remission criteria after 3 cycles.Results The overall rate was 35.4% after at least 3 cycles.3 patients of CR and 19 patients of PR were observed.The mainly adverse reactions were myelo-suppression,digestive tract reaction and hairloss.No obvious water-sodium retention was observed.Conclusion Combination chemotherapy with Docetaxel combined with Oxaliplatin has evident therapeutic effectiveness on advanced NSCLC as the standard seconded-line therapy with tolerable adverse reactions.

关 键 词：多西他赛 奥沙利铂 非小细胞肺癌(NSCLC) 

分 类 号：R734.2[医药卫生—肿瘤]